Multiple sclerosis: Real-world long-term benefits of disease-modifying MS therapy

被引：1
|
作者：
Fyfe I.
机构：
来源：
Nature Reviews Neurology | 2016年 / 12卷 / 7期
关键词：
D O I：
10.1038/nrneurol.2016.76
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：372 / 372
相关论文
共 50 条
  • [41] Real-world Effectiveness Of Initial Treatment With Newer Versus Injectable Disease-modifying Therapies In Pediatric Multiple Sclerosis
    Krysko, K. M.
    Graves, J. S.
    Rensel, M.
    Weinstock-Guttman, B.
    Rutatangwa, A.
    Aaen, G.
    Anita, B.
    Benson, L.
    Chitnis, T.
    Gorman, M.
    Goyal, M. S.
    Harris, Y.
    Krupp, L.
    Lotze, T.
    Mar, S.
    Moodley, M.
    Ness, J.
    Rodriguez, M.
    Rose, J.
    Schreiner, T.
    Tillema, J.
    Waltz, M.
    Casper, T.
    Waubant, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 46 - 47
  • [42] Real-world Effectiveness of Initial Treatment with Newer versus Injectable Disease-modifying Therapies in Pediatric Multiple Sclerosis
    Krysko, Kristen
    Graves, Jennifer
    Rensel, Mary
    Weinstock-Guttman, Bianca
    Rutatangwa, Alice
    Aaen, Gregory
    Belman, Anita
    Benson, Leslie
    Chitnis, Tanuja
    Gorman, Mark
    Goyal, Manu
    Harris, Yolanda
    Krupp, Lauren
    Lotze, Timothy
    Mar, Soe
    Moodley, Manikum
    Ness, Jayne
    Rodriguez, Moses
    Rose, John
    Schreiner, Teri
    Tillema, Jan-Mendelt
    Waltz, Michael
    Casper, T. Charles
    Waubant, Emmanuelle
    NEUROLOGY, 2020, 94 (15)
  • [43] Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies
    Luca Prosperini
    Shalom Haggiag
    Serena Ruggieri
    Carla Tortorella
    Claudio Gasperini
    CNS Drugs, 2023, 37 : 915 - 927
  • [44] Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies
    Prosperini, Luca
    Haggiag, Shalom
    Ruggieri, Serena
    Tortorella, Carla
    Gasperini, Claudio
    CNS DRUGS, 2023, 37 (10) : 915 - 927
  • [45] Characteristics of a population exposed to a disease-modifying drug for multiple sclerosis in the real-world setting (1996-2017)
    Ng, H. S.
    Zhu, F.
    Kingwell, E.
    Zhao, Y.
    Evans, C.
    Svenson, L.
    Fisk, J.
    Marrie, R. A.
    Tremlett, H.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 330 - 331
  • [46] Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies
    Alvarez, Enrique
    Nair, Kavita V.
    Tan, Hiangkiat
    Rathi, Kapil
    Gabler, Nicole B.
    Maiese, Eric M.
    Deshpande, Chinmay
    Shao, Qiujun
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 494 - 502
  • [47] Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry
    Bossart, Jonas
    Kamm, Christian P.
    Kaufmann, Marco
    Stanikic, Mina
    Puhan, Milo A.
    Kesselring, Juerg
    Zecca, Chiara
    Gobbi, Claudio
    Rapold, Irene
    Kurmann, Roland
    Ammann, Sabin
    von Wyl, Viktor
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 60
  • [48] Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysis
    Jiang, Fan
    Zhang, Fenghe
    Su, Yue
    Zhang, Chao
    Chang, Ting
    HELIYON, 2024, 10 (11)
  • [49] Disease-modifying therapy aids cognition in multiple sclerosis
    Amato, Maria Pia
    Krupp, Lauren B.
    NATURE REVIEWS NEUROLOGY, 2020, 16 (10) : 525 - 526
  • [50] Adherence of Adolescents to Multiple Sclerosis Disease-Modifying Therapy
    Thannhauser, Jennifer E.
    Mah, Jean K.
    Metz, Luanne M.
    PEDIATRIC NEUROLOGY, 2009, 41 (02) : 119 - 123
12345